REFERENCES
1. Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019;4:643-54.
2. Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United European Gastroenterol J. 2022;10:1113-20.
3. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56-66.
4. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458-66.
5. Liu JZ, van Sommeren S, Huang H, et al. ; International Multiple Sclerosis Genetics Consortium, International IBD Genetics Consortium. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979-86.
7. Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23:1-13.
8. Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612.
9. Opara J, Małecki A, Małecka E, Socha T. Motor assessment in Parkinson’s disease. Ann Agric Environ Med. 2017;24:411-5.
10. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456-62.
11. Yoo BB, Mazmanian SK. The enteric network: interactions between the immune and nervous systems of the gut. Immunity. 2017;46:910-26.
12. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517-36.
13. Lin JC, Lin CS, Hsu CW, Lin CL, Kao CH. Association between Parkinson’s disease and inflammatory bowel disease: a nationwide taiwanese retrospective cohort study. Inflamm Bowel Dis. 2016;22:1049-55.
14. Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977-2014. Gut. 2019;68:18-24.
15. Weimers P, Halfvarson J, Sachs MC, et al. Inflammatory bowel disease and Parkinson’s disease: a nationwide Swedish cohort study. Inflamm Bowel Dis. 2019;25:111-23.
16. Park S, Kim J, Chun J, et al. Patients with inflammatory bowel disease are at an increased risk of Parkinson’s disease: a South Korean nationwide population-based study. J Clin Med. 2019;8:1191.
17. Peter I, Dubinsky M, Bressman S, et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 2018;75:939-46.
18. Coates MD, Ba DM, Liu G, Dalessio S, Leslie DL, Huang X. Revisiting the association between inflammatory bowel disease and Parkinson’s disease. Inflamm Bowel Dis. 2022;28:850-4.
19. Wang HL, Wang ZY, Tian J, Ma DR, Shi CH. Association between inflammatory bowel disease and Parkinson’s disease: a prospective cohort study of 468,556 UK biobank participants. Front Aging Neurosci. 2023;15:1294879.
20. Loosen SH, Yaqubi K, May P, et al. Association between inflammatory bowel disease and subsequent development of restless legs syndrome and Parkinson’s disease: a retrospective cohort study of 35,988 primary care patients in Germany. Life. 2023;13:897.
21. Choi K, Lee HJ, Han K, Koh SJ, Im JP, Kim JS. Depression in patients with inflammatory bowel disease is associated with increased risk of dementia and Parkinson’s disease: a nationwide, population-based study. Front Med. 2022;9:1014290.
23. Hsu YT, Liao CC, Chang SN, et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriatr Psychiatry. 2015;23:934-40.
24. Camacho-Soto A, Gross A, Searles Nielsen S, Dey N, Racette BA. Inflammatory bowel disease and risk of Parkinson’s disease in Medicare beneficiaries. Parkinsonism Relat Disord. 2018;50:23-8.
25. Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
26. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-63.
27. Freuer D, Meisinger C. Association between inflammatory bowel disease and Parkinson’s disease: a Mendelian randomization study. NPJ Parkinsons Dis. 2022;8:55.
28. Zeng R, Wang J, Jiang R, et al. Investigating causality and shared genetic architecture between neurodegenerative disorders and inflammatory bowel disease. Aging Dis. 2023;14:1349-59.
29. Cui G, Li S, Ye H, et al. Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study. Front Immunol. 2022;13:956005.
30. Yang J, Lin W, Ma Y, et al. Investigation of the causal association between Parkinson’s disease and autoimmune disorders: a bidirectional Mendelian randomization study. Front Immunol. 2024;15:1370831.
31. Witoelar A, Jansen IE, Wang Y, et al. ; International Parkinson’s Disease Genomics Consortium (IPDGC), North American Brain Expression Consortium (NABEC), and United Kingdom Brain Expression Consortium (UKBEC) Investigators. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 2017;74:780-92.
32. Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47:D1005-12.
33. Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links. Gut. 2021;70:408-17.
35. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601-7.
36. Umeno J, Asano K, Matsushita T, et al. Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2011;17:2407-15.
37. Li Y, Chen Y, Jiang L, et al. Intestinal inflammation and Parkinson’s disease. Aging Dis. 2021;12:2052-68.
39. Herrick MK, Tansey MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease? NPJ Parkinsons Dis 2021;7:26.
40. Hui KY, Fernandez-Hernandez H, Hu J, et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. Sci Transl Med. 2018;10:eaai7795.
41. Gopalai AA, Lim JL, Li HH, et al. LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: a case-control association study for Parkinson’s disease. Mol Genet Genomic Med. 2019;7:e604.
42. Kars ME, Wu Y, Stenson PD, et al. The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson’s disease comorbidity. Genome Med. 2024;16:66.
43. Lashgari NA, Roudsari NM, Niknejad A, et al. LRRK2; communicative role in the treatment of Parkinson’s disease and ulcerative colitis overlapping. CNS Neurol Disord Drug Targets. 2024;23:1177-88.
44. Sun S, Hodel M, Wang X, et al. Macrophage LRRK2 hyperactivity impairs autophagy and induces Paneth cell dysfunction. Sci Immunol. 2024;9:eadi7907.
45. Kondo K, Obitsu S, Teshima R. α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol Pharm Bull. 2011;34:1078-83.
46. Bieri G, Brahic M, Bousset L, et al. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019;137:961-80.
47. Bae EJ, Kim DK, Kim C, et al. LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation. Nat Commun. 2018;9:3465.
48. Henderson MX, Cornblath EJ, Darwich A, et al. Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci. 2019;22:1248-57.
49. Berrebi D, Maudinas R, Hugot JP, et al. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn’s disease colon. Gut. 2003;52:840-6.
50. Lesage S, Zouali H, Cézard JP, et al. ; EPWG-IBD Group, EPIMAD Group, GETAID Group. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-57.
51. Bialecka M, Kurzawski M, Klodowska-Duda G, et al. CARD15 variants in patients with sporadic Parkinson’s disease. Neurosci Res. 2007;57:473-6.
52. Sterka D Jr, Rati DM, Marriott I. Functional expression of NOD2, a novel pattern recognition receptor for bacterial motifs, in primary murine astrocytes. Glia. 2006;53:322-30.
53. Beynon V, Cotofana S, Brand S, et al. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. Inflamm Bowel Dis. 2008;14:1033-40.
54. Chauhan VS, Sterka DG Jr, Furr SR, Young AB, Marriott I. NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia. 2009;57:414-23.
55. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203-9.
56. Leclercq S, Mian FM, Stanisz AM, et al. Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior. Nat Commun. 2017;8:15062.
57. Yang J, Zheng P, Li Y, et al. Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Sci Adv. 2020;6:eaba8555.
58. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46:559-64.
59. Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut. 2008;57:1741-3.
60. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016;79:940-9.
61. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-26.
62. Kim S, Kwon SH, Kam TI, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103:627-41.e7.
63. Liu B, Fang F, Pedersen NL, et al. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology. 2017;88:1996-2002.
64. Espinosa-Oliva AM, Ruiz R, Soto MS, et al. Inflammatory bowel disease induces pathological α-synuclein aggregation in the human gut and brain. Neuropathol Appl Neurobiol. 2024;50:e12962.
65. Socała K, Doboszewska U, Szopa A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res. 2021;172:105840.
67. Jia X, Chen Q, Zhang Y, Asakawa T. Multidirectional associations between the gut microbiota and Parkinson’s disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway. Front Cell Infect Microbiol. 2023;13:1296713.
68. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469-80.e12.
69. Cirstea MS, Yu AC, Golz E, et al. Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov Disord. 2020;35:1208-17.
70. Mertsalmi TH, Pekkonen E, Scheperjans F. Antibiotic exposure and risk of Parkinson’s disease in Finland: a nationwide case-control study. Mov Disord. 2020;35:431-42.
71. Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s disease. Ageing Res Rev. 2018;45:53-61.
72. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:S207-9.
73. van Kessel SP, Frye AK, El-Gendy AO, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat Commun. 2019;10:310.
74. Kim CS. Roles of diet-associated gut microbial metabolites on brain health: cell-to-cell interactions between gut bacteria and the central nervous system. Adv Nutr. 2024;15:100136.
75. Gonçalves P, Araújo JR, Di Santo JP. A cross-talk between microbiota-derived short-chain fatty acids and the host mucosal immune system regulates intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:558-72.
76. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66-72.
77. Tan AH, Chong CW, Lim SY, et al. Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann Neurol. 2021;89:546-59.
78. Jamal S, Kumari A, Singh A, Goyal S, Grover A. Conformational ensembles of α-synuclein derived peptide with different osmolytes from temperature replica exchange sampling. Front Neurosci. 2017;11:684.
79. Uversky VN, Li J, Fink AL. Trimethylamine-N-oxide-induced folding of alpha-synuclein. FEBS Lett. 2001;509:31-5.
80. Chen SJ, Kuo CH, Kuo HC, et al. The gut metabolite trimethylamine N-oxide is associated with Parkinson’s disease severity and progression. Mov Disord. 2020;35:2115-6.
81. Sankowski B, Księżarczyk K, Raćkowska E, Szlufik S, Koziorowski D, Giebułtowicz J. Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson’s disease. Clin Chim Acta. 2020;501:165-73.
82. Chung SJ, Rim JH, Ji D, et al. Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson’s disease. Nutrition. 2021;83:111090.
83. Chen QQ, Haikal C, Li W, Li JY. Gut inflammation in association with pathogenesis of Parkinson’s disease. Front Mol Neurosci. 2019;12:218.
84. Drobny A, Ngo PA, Neurath MF, Zunke F, López-Posadas R. Molecular communication between neuronal networks and intestinal epithelial cells in gut inflammation and Parkinson’s disease. Front Med. 2021;8:655123.
85. Dogra N, Mani RJ, Katare DP. The gut-brain axis: two ways signaling in Parkinson’s disease. Cell Mol Neurobiol. 2022;42:315-32.
86. Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P. Is Parkinson’s disease a chronic low-grade inflammatory bowel disease? J Neurol 2020;267:2207-13.
87. Kang X, Ploner A, Pedersen NL, et al. Tumor necrosis factor inhibition and Parkinson disease: a Mendelian randomization study. Neurology. 2021;96:e1672-9.
88. Pinel Ríos J, Madrid Navarro CJ, Pérez Navarro MJ, et al. Association of Parkinson’s disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records. BMJ Open. 2019;9:e025574.
89. Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles Nielsen S. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol. 2018;5:870-5.
90. Dogra N, Jakhmola-Mani R, Potshangbam AM, Buch S, Pande Katare D. CXCR4 as possible druggable target linking inflammatory bowel disease and Parkinson’s disease. Metab Brain Dis. 2023;38:1079-96.
91. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854-9.
92. Huang H, Xu H, Luo Q, et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation: a case report. Medicine. 2019;98:e16163.
93. Sun MF, Zhu YL, Zhou ZL, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018;70:48-60.
94. Zhao Z, Ning J, Bao XQ, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021;9:226.
95. Dailey FE, Turse EP, Daglilar E, Tahan V. The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. Curr Opin Pharmacol. 2019;49:29-33.
96. Reinares-Sebastián A, Esteban-García N, Takada M, Trigo-Damas I. Drug discovery and development for Parkinson’s disease: are preclinical models good enough? Front Aging Neurosci 2025;17:1692592.
97. Ji HF, Shen L. Probiotics as potential therapeutic options for Alzheimer’s disease. Appl Microbiol Biotechnol. 2021;105:7721-30.
98. Gao J, Zhao L, Cheng Y, et al. Probiotics for the treatment of depression and its comorbidities: a systemic review. Front Cell Infect Microbiol. 2023;13:1167116.
99. Liu X, Du ZR, Wang X, et al. Polymannuronic acid prebiotic plus Lacticaseibacillus rhamnosus GG probiotic as a novel synbiotic promoted their separate neuroprotection against Parkinson’s disease. Food Res Int. 2022;155:111067.
100. Sun H, Zhao F, Liu Y, et al. Probiotics synergized with conventional regimen in managing Parkinson’s disease. NPJ Parkinsons Dis. 2022;8:62.
101. Magistrelli L, Amoruso A, Mogna L, et al. Probiotics may have beneficial effects in Parkinson’s disease: in vitro evidence. Front Immunol. 2019;10:969.
102. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013;74:720-6.
